Research Grade Varlilumab
Varlilumabisafullyhumanmonoclonalantibody (mAb) thattargetsCD27, acriticalmoleculeintheactivationpathwayoflymphocytes.LikeCD40, CD27canbeeffectivelymanipulatedwithactivatingantibodiestoinducepotentanti-tumorresponses, andmayresultinlesstoxicitiesduetoitsrestrictedexpressionandregulation.Varlilumabisanovel, first-in-class, agonistCD27antibodythatstimulatestheCD27pathway, whichresultsinT-cellactivationandantitumoractivityintumormodels.Thisfirst-in-human, dose-escalationandexpansionstudyevaluatedthesafety, pharmacology, andactivityofvarlilumabinpatientswithadvancedsolidtumors.
Product Specifications
Product Name Alternative
1F5, CDX-1127, CAS:1393344-72-3
Expression System
Mammalian Cells
Host
Human
Target
CD27Lreceptor, TNFRSF7, T14, CD27antigen, Tumornecrosisfactorreceptorsuperfamilymember7, CD27, T-cellactivationantigenCD27
Clonality
Monoclonal
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Purification
Protein A/G purified from cell culture supernatant.
Concentration
2mg/ml
Endotoxin
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH7.4.
Storage Conditions
Notes
For research use only. Not suitable for clinical or therapeutic use.
Buffer pH
0.01M PBS, pH7.4.
Species
Human
Isotype
IgG1-kappa
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog